- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Australian Biosimilar Trade Group Names New Chair
Health care policy expert Jane Halton, AO, PSM, has been picked for her extensive experience in governmental health affairs.
Australia’s Generic Biosimilars Medicines Association (GBMA) has named health policy expert Jane Halton, AO, PSM, to chair the group in its efforts to expand access and affordable care. The GBMA is a trade association of generic and biosimilar medicine suppliers in Australia. Halton replaces Sylvain Vigneault, who has chaired the GBMA for 2 years.
Halton previously served as chair of the Coalition for Epidemic Preparedness Innovations and co-chair of COVAX, the vaccines component of the ACT Accelerator, a global collaboration to speed up the development and production of coronavirus disease 2019 (COVID-19) tests, treatments, and vaccines. She is also a former secretary of the Australian departments of Health and Finance.
In her biography with the Institute for Health Metrics and Evaluation, a global health research center at the University of Washington, Halton is described as having extensive experience with finance, insurance, risk management, information technology, human resources, health and aging, sport, public policy, and international affairs. She is also an adjunct professor at the University of Sydney and the university of Canberra. She has previously served on the executive board of the World Health Organization.
“To return to my domestic health policy roots and lead the GBMA, at such a significantly important time for Australian patients and our vital health care community, is a challenge I am delighted to embrace,” Halton said. “As we look to the arrival of a COVID-19 vaccine for our citizens, we also need to be vigilant that all Australians continue to receive the medicines they need, when they need them.”
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Top 5 Most-Read Regulatory Articles of 2024
December 25th 2024In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first interchangeability designations for biosimilars referencing ustekinumab, adalimumab, denosumab, and aflibercept, marking key regulatory milestones in improving patient access to cost-effective treatments.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
